Answers are grounded in this paper and cite their sources.
Being the most common mode of death, heart failure related to adult congenital heart disease (ACHD-HF) will be one of the main challenges for the ACHD community in the coming years. With increasing number of ACHD-HF patients and an increase in ACHD-HF related admissions, there is an increasing demand for advanced HF therapies such as the use of ventricular assist devices and transplantation. Unfamiliarity with the underlying anatomy and pathophysiology, a higher peri-operative transplant mortality and the absence of specific transplant indication criteria put our patients at a disadvantage, making them less attractive candidates for transplant listing. The development of an advanced ACHD-HF service as part of a larger transplant program is a logical/necessary/mandatory next step to optimize and guide clinical care and increase access to advanced HF therapies for ACHD-HF patients. Ultimately increasing knowledge and building evidence should result in better quality of care and improved outcomes for ACHD-HF patients. The purpose of this review article is to provide a sense on how we are evaluating ACHD-HF patients, identifying those who may benefit from advanced HF therapy and eventually deciding on who should be listed for transplant.
No takes yet. Share an insight, caveat, or question.
Bruaene et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: